BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes

WILMINGTON, Del., Jan. 10, 2018 -- (Healthcare Sales & Marketing Network) -- AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States. BYDUREON BCi... Biopharmaceuticals, Endocrinology, Product Launch AstraZeneca, BYDUREON BCise, exenatide

Source: HSMN NewsFeed - January 10, 2018 Category: Pharmaceuticals Source Type: news